Abstract: Provided is a display device including a display panel defining a display region and a non-display region, and including a base layer, a light-emitting element layer above the base layer and including a light-emitting element, and an organic encapsulation layer above the light-emitting element and including a protrusion protruding along a thickness direction of the display panel, at least partially overlapping the display region, and configured to refract a portion of light generated in the display region, an input-sensing unit above the display panel, and including a sensing electrode overlapping the display region, and a signal line connected to the sensing electrode, and a window above the input-sensing unit, and including an optically transparent base substrate, the input-sensing unit or the window including an optical structure overlapping the protrusion.

Abstract: The present invention relates to a novel AUTOTAC chimeric compound in which a new p62 ligand and a target-binding ligand are connected by a linker, a stereoisomer, hydrate, solvate or prodrug thereof, and a pharmaceutical or food composition for the prevention or treatment of diseases by degrading the target protein including the same as an active ingredient. They can target specific proteins to adjust their concentrations, and can also deliver drugs and other small molecule compounds to lysosomes. The AUTOTAC chimeric compound according to the present invention can be usefully used as a pharmaceutical composition for the prevention, amelioration or treatment of various diseases by selectively eliminating specific proteins.

Abstract: The present invention provides a compound represented by the following Chemical Formula 1 or a pharmaceutically acceptable salt thereof which can be effectively used for preventing or treating obesity or metabolic syndrome, and a pharmaceutical composition comprising the same. in Chemical Formula 1, R1 and R2 are the same as defined in the specification.

Abstract: Disclosed is a liquid crystal display (LCD) smart window configured such that a transparent LCD device is mounted in a double-glazed window. The LCD smart window includes an inner glass sheet located in an indoor space, an outer glass sheet spaced apart from the inner glass sheet by a predetermined gap and located so as to be exposed to the outside of a building, a transparent LCD device located in a space between the inner glass sheet and the outer glass sheet to display an image, a window frame supporting upper and lower surfaces and both side surfaces of the inner glass sheet and the outer glass sheet, and a light source secured to the window frame to emit light to at least one surface of the outer glass sheet.

Abstract: Disclosed is a liquid crystal display (LCD) smart window configured such that a transparent LCD device is mounted in a double-glazed window. The LCD smart window includes an inner glass sheet located in an indoor space, an outer glass sheet spaced apart from the inner glass sheet by a predetermined gap and located so as to be exposed to the outside of a building, a transparent LCD device located in a space between the inner glass sheet and the outer glass sheet to display an image, a window frame supporting upper and lower surfaces and both side surfaces of the inner glass sheet and the outer glass sheet, and a light source secured to the window frame to emit light to at least one surface of the outer glass sheet.

Abstract: The present invention relates to a novel p62 ligand compound, a stereoisomer, hydrate, solvate or prodrug thereof, and a pharmaceutical or food composition for preventing or treating proteinopathies comprising the same as an active ingredient. The p62 ligand compound according to the present invention can be usefully used as a pharmaceutical composition for the prevention, amelioration or treatment of various proteinopathies by activating autophagy in cells and thus selectively eliminating in vivo proteins, organelles and aggregates.

Abstract: Proposed is a primer composition for a recombinase-polymerase amplification reaction for rapid diagnosis of Israeli acute paralysis virus and use thereof. A genomic RNA of Israeli acute paralysis virus (IAPV) is isolated from honey bees to analyze a nucleotide sequence of IAPV, and a primer pair capable of being detected by a recombinase-polymerase amplification method was prepared based on the IAPV RNA sequence. In addition, the optimal conditions of the prepared primer pair were confirmed, and it was confirmed that the genomic RNA of IAPV could be rapidly detected and diagnosed.

Abstract: One aspect of the disclosure relates to a cargo delivery system comprising an autophagy targeting ligand and a target-binding ligand. In one aspect of the disclosure, by comprising an autophagy targeting ligand, cargo, which is a target-binding ligand that specifically binds to a target, is delivered to the p62 protein and autophagy is activated, so that depending on the type of target-binding ligand used, a target to be degraded can be selectively and directly removed. Accordingly, the cargo delivery system according to an aspect of the disclosure may be used in pharmaceutical compositions or food compositions for preventing, alimerating, and treating various diseases.

Abstract: A display device includes a display panel, a mold frame at least partially surrounding the display panel, and a bracket at least partially overlapping the mold frame. Each of the mold frame and the bracket includes an electrically conductive material, and the mold frame and the bracket are electrically connected to each other.

Abstract: The present invention relates to a novel p62 ligand compound, a stereoisomer, hydrate, solvate or prodrug thereof, and a pharmaceutical or food composition for preventing or treating proteinopathies comprising the same as an active ingredient. The p62 ligand compound according to the present invention can be usefully used as a pharmaceutical composition for the prevention, amelioration or treatment of various proteinopathies by activating autophagy in cells and thus selectively eliminating in vivo proteins, organelles and aggregates.

Abstract: A display device includes a display panel, a mold frame at least partially surrounding the display panel, and a bracket at least partially overlapping the mold frame. Each of the mold frame and the bracket includes an electrically conductive material, and the mold frame and the bracket are electrically connected to each other.

Abstract: The present invention relates to a novel AUTOTAC chimeric compound in which a new p62 ligand and a target-binding ligand are connected by a linker, a stereoisomer, hydrate, solvate or prodrug thereof, and a pharmaceutical or food composition for the prevention or treatment of diseases by degrading the target protein including the same as an active ingredient. They can target specific proteins to adjust their concentrations, and can also deliver drugs and other small molecule compounds to lysosomes. The AUTOTAC chimeric compound according to the present invention can be usefully used as a pharmaceutical composition for the prevention, amelioration or treatment of various diseases by selectively eliminating specific proteins.

Abstract: A display device includes a display panel, a mold frame at least partially surrounding the display panel, and a bracket at least partially overlapping the mold frame. Each of the mold frame and the bracket includes an electrically conductive material, and the mold frame and the bracket are electrically connected to each other.

Abstract: The present invention relates to a novel p62 ligand compound, a stereoisomer, hydrate, solvate or prodrug thereof, and a pharmaceutical or food composition for preventing or treating misfolded protein diseases comprising the same as an active ingredient. The p62 ligand compound according to the present invention can be usefully used as a pharmaceutical composition for the prevention, amelioration or treatment of various proteinopathies by activating selective autophagy in cells and thus selectively eliminating in vivo proteins, organelles and aggregates.

Abstract: A display device includes a display panel, a mold frame at least partially surrounding the display panel, and a bracket at least partially overlapping the mold frame. Each of the mold frame and the bracket includes an electrically conductive material, and the mold frame and the bracket are electrically connected to each other.

Abstract: The present invention provides a compound represented by the following Chemical Formula 1 or a pharmaceutically acceptable salt thereof which can be effectively used for preventing or treating obesity or metabolic syndrome, and a pharmaceutical composition comprising the same. in Chemical Formula 1, R1 and R2 are the same as defined in the specification.

Abstract: A connector device included in an electronic device is provided. The connector device includes a connector main body including at least one hole and a slot, at least one housing coupled to the connector main body to shield the at least one hole and the slot, a shielding member included in a rear face of the at least one housing, at least one coupling portion included in each of opposite side faces of the at least one housing so as to couple the at least one housing, and at least one fixing portion included in one end of the at least one coupling portion and fixed to a board included in the electronic device. Various other embodiments are possible.

Abstract: A connector device included in an electronic device is provided. The connector device includes a connector main body including at least one hole and a slot, at least one housing coupled to the connector main body to shield the at least one hole and the slot, a shielding member included in a rear face of the at least one housing, at least one coupling portion included in each of opposite side faces of the at least one housing so as to couple the at least one housing, and at least one fixing portion included in one end of the at least one coupling portion and fixed to a board included in the electronic device. Various other embodiments are possible.

Abstract: Disclosed are a backlight unit and a liquid crystal display device including the same to stably fix a light guide plate. The backlight unit includes a guide disposed between a cover bottom, on which a light guide plate is mounted, and the light guide plate, the guide having a plurality of projections in an area in which the guide contacts the light guide plate.